^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Pancreatic Cancer
    Drug:gemcitabine (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ASCO.org
    Title:

    Metastatic Pancreatic Cancer: ASCO Guideline Update

    Published date:
    08/05/2020
    Excerpt:
    Recommendations…First-Line Treatment…Gemcitabine plus nab-paclitaxel is recommended…Recommendations…First-Line Treatment…Gemcitabine alone is recommended…The addition of nabpaclitaxel or capecitabine or erlotinib to gemcitabine may be offered in this setting…
    DOI:
    10.1200/JCO.20.01364 Journal of Clinical Oncology
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    JAMA Oncol
    Title:

    Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment

    Published date:
    12/14/2020
    Excerpt:
    ...343 patients (66.0%) received adjuvant chemotherapy, of whom 68 (19.8%) received FOLFIRINOX, 201 (58.6%) received gemcitabine-based chemotherapy, 14 (4.1%) received capecitabine, 45 (13.1%) received a combination or other agents...adjuvant chemotherapy after neoadjuvant FOLFIRINOX and resection of pancreatic cancer was associated with improved survival only in patients with pathology-proven node-positive disease.
    Secondary therapy:
    FOLFIRINOX
    DOI:
    10.1001/jamaoncol.2020.3537